Xie et al reported a prognostic model for a patient with acute-on-chronic liver failure due to hepatitis B that is treated with plasma-exchange based liver support. This can help to identify a patient who requires more aggressive management. The authors are from Zhejiang University in Hangzhou, China.
Patient selection: ACLF on a plasma exchange life support system (artificial liver support system, ALLS)